Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Naturhouse Health, S.A. is a Spanish company specializing in the nutrition, dietetics, and weight management sector. It develops, manufactures, and sells food supplements derived from natural extracts to support nutrient intake, along with dietetic foods and drinks such as breakfast options, snacks, and meal replacements. The company also offers cosmetics and body care products, including skincare for slimming processes like cellulite treatments and firming solutions, as well as anti-aging items, herbal remedies, and natural cosmetics. Products are distributed through directly operated stores and an extensive network of franchised Naturhouse centers, primarily in Spain, Italy, France, Poland, and other international markets. Incorporated in 1991 and headquartered in Madrid, Naturhouse Health, S.A. operates as the parent of the Naturhouse Group, focusing on export, wholesale, and retail sales. Its activities emphasize marketing dietary products and related publications, playing a key role in the consumer defensive and specialty retail sectors by addressing wellness and beauty needs. With around 184-191 employees, the company maintains a strong presence in packaged foods and other specialty retailers.
€2.55
€0.02 (-0.78%)
EOD Jun 23, 2026 · Twelve Data
Margins and capital returns are both well above average: 27.80% operating margin, ROIC at 35.55%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue declined 3.6% YoY. The question is whether this is cyclical or a structural shift.
Even for strong businesses, today's 15x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
15.1x earnings, 13.1x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€48M
▼ -3.6% YoY
Net Income (TTM)
€10M
▲ +2.3% YoY
Op. Margin
27.80%
▲ +1.2pp YoY
ROIC
35.55%
▲ +7.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€12M
▲ +4.0% YoY
Op. Cash Flow (TTM)
€14M
▼ -1.7% YoY
Net Debt
-€12M
Net Cash Position
Cash & Equiv.
€14M
3Y CAGR: -3.1%
3Y CAGR: +23.9%
Continue Research